(Wellesley, MA) – June 2016 – Cure Alzheimer’s Fund is announcing that Charity Navigator has assigned the organization a score of 100 percent regarding its overall financial health. The nation’s largest and most-utilized evaluator of charities, Charity Navigator assigned this score by evaluating two areas of the Fund’s performance – financial health and accountability/transparency – through the IRS Form 990.
“It is gratifying to see Charity Navigator once again recognize the financial health and transparency of Cure Alzheimer’s Fund with its highest score,” said Tim Armour, president and CEO of Cure Alzheimer’s Fund. “Our donors give to us because they want to find effective treatments for Alzheimer’s disease. Charity Navigator’s score further demonstrates our good stewardship of those donor dollars.”
In 2016, Charity Navigator modified its scoring system. To better reflect the health and fiscal responsibility of rated charities, they have reworked their seven financial metrics, which has resulted in this year’s score. Cure Alzheimer’s Fund has previously received four stars from Charity Navigator five times, an achievement only attained by 6 percent of charities.
“Cure Alzheimer’s Fund Board of Directors and staff work hard to ensure that the organization is performing at the highest level,” said Mr. Armour. “Our mission is to find a cure for this terrible disease, and we appreciate Charity Navigator’s acknowledgement of our operations. Thank you to Charity Navigator and to all who move our work forward.”
Cure Alzheimer’s Fund is a non-profit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has contributed over $40 million to research, and its funded initiatives have been responsible for several key breakthroughs – including the groundbreaking “Alzheimer’s in a Dish.” With 100 percent of donations going directly to research, Cure Alzheimer’s has been able to support some of the best scientific minds in the field of Alzheimer’s research.